Published Date: 08 Oct 2025
The American Cancer Society has released a report on occurrence and outcomes in the United States for this subtype of breast cancer. Findings show an estimated 33,600 women will be diagnosed with lobular breast cancer or ...
Read Full NewsTrial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.
The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.
COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension
Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial
FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates
1.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
2.
Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco
3.
24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.
4.
Thriving while surviving: Understanding the social needs of cancer survivors
5.
Insurance Claim Denials for Preventive Care More Common in At-Risk Patients
1.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
2.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
3.
Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms
4.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
5.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation